Table 1.
List of TCGA and CCLE samples analyzed in this study
| TCGA-Acronym | Cancer | Tumor Samples Processed (%) | Normal-Adjacent Samples Processed (%) | Cell Lines Processed (%) |
|---|---|---|---|---|
| TCGA-ACC | adrenocortical carcinoma | 79 (0.9) | 0 | 0 |
| TCGA-BLCA | bladder urothelial carcinoma | 408 (4.6) | 19 (2.6) | 26 (3.2) |
| TCGA-BRCA | breast | 1,094 (12.3) | 113 (15.5) | 52 (6.5) |
| TCGA-CESC | cervical squamous cell carcinoma and endocervical adenocarcinoma | 304 (3.4) | 3 (0.4) | 22 (2.7) |
| TCGA-CHOL | cholangiocarcinoma | 36 (0.4) | 9 (1.2) | 0 |
| TCGA-COAD | colon adenocarcinoma | 244 (2.7) | 41 (5.6) | 58 (7.2) |
| TCGA-DLBC | lymphoid neoplasm diffuse large B cell lymphoma | 48 (0.5) | 0 | 54 (6.7) |
| TCGA-ESCA | esophageal carcinoma | 161 (1.8) | 11 (1.5) | 25 (3.1) |
| TCGA-GBM | glioblastoma | 117 (1.32) | 5 (0.7) | 0 |
| TCGA-HNSC | head and neck squamous cell carcinoma | 458 (5.2) | 44 (6.0) | 32 (4) |
| TCGA-KICH | kidney chromophobe | 65 (0.7) | 24 (3.3) | 0 |
| TCGA-KIRC | kidney renal clear cell carcinoma | 474 (5.3) | 72 (9.9) | 21 (2.6) |
| TCGA-KIRP | kidney renal papillary cell carcinoma | 288 (3.2) | 32 (4.4) | 0 |
| TCGA-LAML | acute myeloid leukemia | 131 (1.5) | 0 | 0 |
| TCGA-LGG | brain lower grade glioma | 508 (5.7) | 0 | 63 (7.9) |
| TCGA-LIHC | liver hepatocellular carcinoma | 371 (4.2) | 50 (6.8) | 30 (3.7) |
| TCGA-LUAD | lung adenocarcinoma | 506 (5.7) | 59 (8.1) | 0 |
| TCGA-LUSC | lung squamous cell carcinoma | 501 (5.6) | 49 (6.7) | 184 (22.9) |
| TCGA-MESO | mesothelioma | 86 (1) | 0 | 1 (0.1) |
| TCGA-OV | ovarian | 305 (3.4) | 0 | 45 (5.6) |
| TCGA-PAAD | pancreatic adenocarcinoma | 182 (2) | 4 (0.5) | 41 (5.1) |
| TCGA-PCPG | pheochromocytoma and paraganglioma | 178 (2) | 3 (0.4) | 0 |
| TCGA-PRAD | prostate adenocarcinoma | 497 (5.6) | 52 (7.1) | 7 (0.9) |
| TCGA-READ | rectum adenocarcinoma | 94 (1.1) | 10 (1.4) | 0 |
| TCGA-SARC | sarcoma | 259 (2.9) | 2 (0.3) | 38 (4.7) |
| TCGA-SKCM | skin cutaneous melanoma | 103 (1.2) | 1 (0.1) | 51 (6.4) |
| TCGA-STAD | stomach adenocarcinoma | 375 (4.2) | 32 (4.4) | 37 (4.6) |
| TCGA-TGCT | testicular germ cell tumors | 150 (1.7) | 0 | 0 |
| TCGA-THCA | thyroid carcinoma | 426 (4.8) | 58 (7.9) | 12 (1.5) |
| TCGA-THYM | thymoma | 119 (1.3) | 2 (0.3) | 0 |
| TCGA-UCEC | uterine corpus endometrial carcinoma | 180 (2.0) | 35 (4.8) | 3 (0.4) |
| TCGA-UCS | uterine carcinosarcoma | 56 (0.6) | 0 | 0 |
| TCGA-UVM | uveal melanoma | 80 (0.9) | 0 | 0 |
Percent contribution of samples analyzed in each dataset is included in the parenthesis.